Dr. Shai Gozani
to and note. you, several Thank updates provide shareholders may lines I that to updates. our product we catalysts have DPNCheck identify two With Tom. on will regard growth want
planning generation first quarter First, to device the United in launch the second we are States XXXX. of DPNCheck in the
into going combination production a be multi-year will R&D This quarter. a of is this We effort.
technological We device's at will the benefits customer provide the launch. details and of features on time
support broad terms, our will and it further we solidify in with Advantage Medicare believe first adoption mover a advantage. However,
production the component phase Now due over by the constraints to second worldwide device into market we shortage to course generation need created electronic the of XXXX. will the
Care. management Based that Second, Value has and years markets. value-based team experience as SVP Advantage sales can Health Su's yesterday Medicare we & believe our announced business we Population leadership We grow other of strategy substantially Medicare to Advantage. and Su in under of addition XX Su the development Bell in DPNCheck
been we affiliated provided those use with within terminology, large provision of Medicare has care value-based have Advantage to networks, rather number Medicare adopted is than insurers quality tied when For reimbursement start. largest the provider of by their so unfamiliar more of this good is is services. simply care value-based a DPNCheck some a of Advantage closely model. the care for for
Moving are specific over-the-counter beyond pain to chronic the lower treatments for syndromes. for expanding we platform, prescription extremity Quell use neuromodulation pain to
FDA of treatment in a indication. request population use affects inadequate in program In next are Quell indicated for filed clinical Subject should prescription to of fibromyalgia. next novo of treat had this up that our for medical de the this timelines, we de indication announced regulatory we Quell fourth FDA the with novo month, the earlier development symptoms fibromyalgia X% to year. fibromyalgia, chronic this for designation for quarter adults focused If US. go-to-market the of the granted complex lead believe we are we in and authorization we this of the July, we we breakthrough of the time, received the to that adult and initial options review is condition pain second Our the process indication from in the to then record revenue launch fibromyalgia will treatment be the expect strategy. ongoing year first device Quell for on half At and
neuropathy, our of and on information our further prescription last is another get to provide we is peripheral will launch. update approach strategies as induced closer commercial on which one the programs. My We
second of timelines for date the next look are this be target file National multicenter, of If novo trial and quarter first There end to a we patients Quell a in side and CIPN is serious that effects. to results triple-blinded XXXX. randomized, limited expect treatment This Cancer XXXX. a options we for positive, patients hold, condition of may over enrollment the Based requests on As chemotherapy. if are complication cause with the a in in the effectiveness is half funding we may de and half enrollment, by reminder, indication out watch receiving sham-controlled will that of of the trial have read year this for occurs and in indication those are in those the the CIPN. to to few Institute used disabling position the
efficient markets. and to is diagnostic unmet at novel So point. the for neurology questions this We'll pain a in therapeutic committed needs happy summary, with are prepared products NeuroMetrix operationally take comments. organization in and and Those be
